Creative Biolabs delivers end-to-end Escherichia coli microbiome solutions—strain access, engineering, mechanism-of-action studies, safety profiling, and scalable bioprocessing—so academic and biotech teams can generate decision-ready data, reduce risk, and move confidently from exploratory ideas to robust, reproducible results.
Chosen by R&D teams that need mechanism-first analytics, standardized wet-lab workflows, and transparent project management tailored to E. coli research.
E. coli spans commensal, engineered, and probiotic lineages, demanding platform methods that align genetic design, fermentation performance, and host-interaction biology. An experienced partner connects these layers into coherent datasets and clear, comparable readouts.
Creative Biolabs integrates genetic stability, MoA screening, advanced epithelial/co-culture models, and scale-aware fermentation under one roof—accelerating iteration cycles while mitigating biosafety and antimicrobial resistance (AMR) concerns common to E. coli programs. Evidence generation includes siderophore/microcin-linked competitive effects and barrier-relevant outcomes.
Comprehensive support for E. coli Nissle 1917 (EcN): authenticated strain access, identity confirmation, fermentation process development, stabilization and formulation, and mechanism-aligned in vitro evaluation. Packages span feasibility to pilot scale with QC gates, enabling EcN programs to benchmark colonization-adjacent traits and microcin/siderophore-associated competitive effects with consistent, comparable data.
Engineering for E. coli includes CRISPR/recombineering, promoter/operon tuning, vector selection, auxotrophy/safety-switch design, and chassis fitness optimization. We couple genotype to phenotype via multiplex growth and expression profiling, mapping burden, copy-number effects, and stress responses to measurable outputs that guide construct pruning and scale-up readiness across E. coli backgrounds.
For engineered E. coli, we quantify segregational and structural stability across serial passages with and without selection pressure, track copy number and expression, and screen for off-target events via WGS/targeted panels. Results pinpoint circuit fragilities, plasmid addiction needs, or integration-site effects to de-risk downstream fermentation and host-interaction experiments.
We build mechanism-relevant assays for E. coli: competitive exclusion against pathobionts, siderophore/microcin-linked effects, metabolite outputs, and barrier integrity or cytokine shifts. Data packages include orthogonal readouts (e.g., CFU dynamics, TEER, reporter panels) to anchor claims in quantifiable biology and enable apples-to-apples comparisons across variants.
Using epithelial monolayers (Caco-2/HT29-MTX), primary/organoid-derived intestinal models, and immune-competent co-cultures, we assess E. coli adhesion/colonization, tight junction markers, mucus interactions, and host response signatures. These models provide barrier-relevant endpoints without overfitting to a single cell line, supporting iterative design and formulation refinement.
We translate E. coli bench runs to robust fed-batch/continuous regimes by optimizing carbon feed, DO, pH, and temperature, then scale by transfer-ready criteria (e.g., kLa, oxygen uptake rate). Deliverables balance biomass/viability with expression targets and link upstream parameters to downstream stability, drying, and packaging needs.
For E. coli lines, we screen virulence genes and mobile elements, evaluate prophage/lysogeny risk, and quantify endotoxin and residual DNA per harmonized test chapters. Outputs support internal risk management and communication with oversight bodies in research contexts.
We provide MIC/MLC panels for E. coli using current CLSI methods and breakpoints, complemented by AMR-gene profiling and cross-resistance interpretation. Results contextualize selective markers and environmental exposures, informing strain stewardship and documentation for research governance.
Define goals, strain background, design constraints, and biosafety/AMR considerations; align on decision thresholds and timelines.
Source or receive E. coli, authenticate, and establish seed stocks; baseline genotype/phenotype.
Prototype stability, MoA, and host-interaction assays; confirm signal windows and QC metrics.
Optimize fermentation (feed/DO/pH), establish CPPs and sampling plans, and bridge to downstream steps.
Run genetic element screens, endotoxin/residual-DNA tests, and prophage assessments; compile risk notes.
Deliver annotated protocols, raw/processed data, and recommendations; support internal replication.
One coordinated program connects strain work, assay development, safety analytics, and bioprocessing for a seamless path from concept to dataset.
A broad menu of epithelial, co-culture, and advanced in vitro systems is configured to match goals, timelines, and budgets.
Methods, controls, and sampling plans are designed to translate smoothly from bench experiments to pilot-ready processes.
Standardized protocols, audited documentation, and reproducible workflows support consistent results and confident internal review.
Pick only the modules you need; transparent checkpoints keep scope, deliverables, and timelines aligned throughout the project.
Concise summaries, annotated data, and practical next-step recommendations enable faster go/no-go decisions across R&D teams.
Engineered E. coli supports high-yield expression of insulin analogs, somatropin, enzymes, and peptides, enabling process development, comparability studies, and mechanism assays with traceable quality controls from bench-scale screening to scalable upstream operations.
Optimized E. coli strains produce antigens and VLP components for immunogenicity models, epitope mapping, and formulation screening, accelerating design–build–test cycles and standardized analytics across bacterial and viral targets with reproducible, lot-to-lot performance.
Non-pathogenic E. coli, including Nissle 1917, can be engineered as living biosensors or competitive strains to study microenvironmental sensing, metabolite modulation, pathogen suppression, colonization dynamics, and barrier-relevant host responses in controlled models.
E. coli remains the canonical chassis for genetic circuits, CRISPR tool development, codon-reduced genomes, and pathway prototyping—advancing studies of replication, gene regulation, and burden, while de-risking constructs before scale-up or formulation optimization.
Pathogenic and engineered E. coli panels power high-throughput screening, susceptibility profiling, and mode-of-action studies, clarifying targets and resistance mechanisms while informing stewardship strategies and experimental design for antibacterial research programs.
Pathway-optimized E. coli converts renewable feedstocks or waste-derived intermediates into organic acids, alcohols, platform chemicals, and biopolymers, enabling carbon-flux control, stress mapping, and robustness criteria that translate from microtiter screens to pilot-scale runs.
Creative Biolabs successfully engineered E. coli Nissle 1917 (EcN) to biosynthesize (R)-β-hydroxybutyrate (3HB), a key ketone body metabolite with physiological relevance. Using CRISPR/Cas9-mediated genome editing, specific genes (tB–pA–pB) were integrated into the malEK locus, while lA was deleted to optimize carbon flux toward 3HB formation. PCR and sequencing verified correct gene insertion and knockout events, and antibiotic sensitivity profiling confirmed strain stability.
This engineered EcN strain demonstrates how probiotic chassis organisms can be transformed into efficient microbial factories for value-added metabolite production, bridging synthetic biology with next-generation probiotic applications.
Download the case study brochure from Creative Biolabs to see the step-by-step construction, validation data, and deliverables for a 3HB-producing E. coli Nissle 1917 chassis.
Below is a curated list of related research-use products to support ongoing E. coli studies
Product Name | Catalog No. | Target | Product Overview | Size | Price |
---|---|---|---|---|---|
Escherichia coli Nissle 1917 | LBSX-0522-GF116 | Escherichia | A probiotic strain with proven efficacy in inducing and maintaining remission of ulcerative colitis. | – | |
Escherichia coli -10^3 | LBGF-0926-GF57 | Escherichia coli | Each instant-dissolve pellet delivers 10–100 CFU per 0.1 mL and provides 6 hours of stability after rehydration. | – | |
Escherichia coli -10^5 | LBGF-0926-GF58 | Escherichia coli | Each instant-dissolve pellet delivers 10^3-10^4 CFU per 0.1 mL and provides 6 hours of stability after rehydration. | – | |
Escherichia coli -10^8 | LBGF-0926-GF59 | Escherichia coli | Each instant-dissolve pellet delivers 10^6-10^7 CFU per 0.1 mL and provides 6 hours of stability after rehydration. | – | |
Escherichia coli Nissle 1917 △pMUT1△pMUT2 | LBGF-0324-GF1 | Escherichia | Gene-modified strain with removal of two cryptic plasmids pMUT1 and pMUT2. | – | |
Escherichia coli EPEC DNA Standard | LBGF-0125-GF75 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Escherichia coli DNA Standard | LBGF-0125-GF77 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Escherichia coli ETEC DNA Standard | LBGF-0125-GF79 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Escherichia coli EIEC DNA Standard | LBGF-0125-GF88 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Escherichia coli EHEC DNA Standard | LBGF-0125-GF137 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Escherichia coli EHEC DNA Standard | LBGF-0125-GF145 | Escherichia DNA Standard | DNA standard for quantitative research, assay development, verification, validation, and QC. | – | |
Inactivated Escherichia coli | LBGF-0125-GF160 | Inactivated Escherichia | Escherichia coli has been inactivated. | – | |
Inactivated Escherichia coli EIEC | LBGF-0125-GF161 | Inactivated Escherichia | Escherichia coli EIEC has been inactivated. | – | |
Inactivated Escherichia coli EAEC | LBGF-0125-GF162 | Inactivated Escherichia | Escherichia coli EAEC has been inactivated. | – | |
Inactivated Escherichia coli ETEC | LBGF-0125-GF163 | Inactivated Escherichia | Escherichia coli ETEC has been inactivated. | – | |
Inactivated Escherichia coli EHEC O157:H7 | LBGF-0125-GF194 | Inactivated Escherichia | Escherichia coli EHEC O157:H7 has been inactivated. | – | |
Inactivated Escherichia coli EPEC | LBGF-0125-GF210 | Inactivated Escherichia | Escherichia coli EPEC has been inactivated. | – | |
Inactivated Escherichia coli phage T7 | LBGF-0125-GF217 | Inactivated Phage | Escherichia coli phage T7 has been inactivated. | – | |
Inactivated Escherichia coli bacteriophage PhiX174 | LBGF-0125-GF218 | Inactivated Phage | Escherichia coli bacteriophage PhiX174 has been inactivated. | – | |
Inactivated Escherichia coli bacteriophage Qbeta | LBGF-0125-GF219 | Inactivated Phage | Escherichia coli bacteriophage Qbeta has been inactivated. | – | |
Inactivated Escherichia coli bacteriophage T1 | LBGF-0125-GF220 | Inactivated Phage | Escherichia coli bacteriophage T1 has been inactivated. | – | |
Inactivated Escherichia coli bacteriophage T4 | LBGF-0125-GF221 | Inactivated Phage | Escherichia coli bacteriophage T4 has been inactivated. | – | |
Inactivated Escherichia coli bacteriophage MS2 | LBGF-0125-GF222 | Inactivated Phage | Escherichia coli bacteriophage MS2 has been inactivated. | – |
Creative Biolabs employs CRISPR/Cas9, recombineering, and modular plasmid systems to enable precise genome editing, pathway reconstruction, and promoter tuning for E. coli strains, including Nissle 1917 and other research-relevant backgrounds.
Yes. We conduct long-term passaging, copy number tracking, expression quantification, and WGS validation to evaluate genetic and phenotypic stability of engineered E. coli constructs under diverse growth and process conditions.
We apply epithelial, immune cell, and organoid-based co-culture models to examine E. coli adhesion, colonization, and host response markers, producing quantitative datasets that reflect real biological relevance.
Clients receive authenticated E. coli strains, validated plasmid constructs, comprehensive data packages, and summarized experimental reports detailing workflow parameters, verification results, and performance metrics for reproducibility and internal review.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2025 Creative Biolabs. All Rights Reserved.